title: Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis.
abstract: BACKGROUND
  Though gastric cancer screening by X-ray examination has been confirmed to be effective for reducing gastric cancer mortality, decreases in efficiency have been pointed out. Establishment of an effective screening system, focusing on high-risk status such as Helicobacter pylori infection and atrophic gastritis, is desirable. To date, combined use of serum anti-Helicobacter pylori antibodies and pepsinogen measurement has been assessed prospectively in participants in opportunistic and workplace health check-ups; however, there are no reports of population-based cohort study.
  
  
  OBJECTIVE
  To clarify the population-based risk of Helicobacter pylori infection and atrophic gastritis for gastric cancer, a cohort study was conducted in rural towns in Kyoto Prefecture.
  
  
  METHODS
  Subjects were 1,011 males and 1,848 females recruited in a health check-up in 1987. Their serum was examined for anti-Helicobacter pylori antibodies and pepsinogen I and II. Gastric cancer cases were assessed from the cancer registry of those towns.
  
  
  RESULTS
  Up to the end of 1996, 33 males and 28 females developed gastric cancer. A sex- and age-adjusted hazard ratio was calculated by Cox's proportional model. Helicobacter pylori infection increased the risk of gastric cancer even when the subjects had no atrophy (hazard ratio =4.20; 95% confidence interval, 0.96-18.40). The risk increased further when they had both Helicobacter pylori infection and atrophy (hazard ratio =11.23; 95% confidence interval, 2.71-46.51). Subjects with atrophy but negative for anti-Helicobacter pylori antibodies had the highest risk (hazard ratio =14.81; 95% confidence interval, 2.47-88.80).
  
  
  CONCLUSIONS
  A high-risk group for gastric cancer can be selected by serological prescreening.
authors.affiliation: Department of Medical Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyama-kita, Higashinada-ku, Kobe, Japan. mizuno@kobepharma-u.ac.jp
authors.forename: Shigeto
authors.initials: S
authors.lastname: Mizuno
authors.forename: Ikuya
authors.initials: I
authors.lastname: Miki
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Ishida
authors.forename: Masaru
authors.initials: M
authors.lastname: Yoshida
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Onoyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Azuma
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Habu
authors.forename: Hideto
authors.initials: H
authors.lastname: Inokuchi
authors.forename: Kotaro
authors.initials: K
authors.lastname: Ozasa
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Miki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D005757:Gastritis, Atrophic / Q000453:epidemiology*; D016481:Helicobacter Infections / Q000453:epidemiology*; D016480:Helicobacter pylori; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000453:epidemiology*